Metformin and Cancer, an Ambiguanidous Relationship.
| cam.issuedOnline | 2022-05-19 | |
| dc.contributor.author | Skuli, Sarah J | |
| dc.contributor.author | Alomari, Safwan | |
| dc.contributor.author | Gaitsch, Hallie | |
| dc.contributor.author | Bakayoko, A'ishah | |
| dc.contributor.author | Skuli, Nicolas | |
| dc.contributor.author | Tyler, Betty M | |
| dc.contributor.orcid | Alomari, Safwan [0000-0002-7595-818X] | |
| dc.contributor.orcid | Gaitsch, Hallie [0000-0002-6656-607X] | |
| dc.contributor.orcid | Tyler, Betty M [0000-0001-9800-6969] | |
| dc.date.accessioned | 2022-05-21T08:00:21Z | |
| dc.date.available | 2022-05-21T08:00:21Z | |
| dc.date.issued | 2022-05-19 | |
| dc.date.updated | 2022-05-21T08:00:20Z | |
| dc.description.abstract | The deregulation of energetic and cellular metabolism is a signature of cancer cells. Thus, drugs targeting cancer cell metabolism may have promising therapeutic potential. Previous reports demonstrate that the widely used normoglycemic agent, metformin, can decrease the risk of cancer in type 2 diabetics and inhibit cell growth in various cancers, including pancreatic, colon, prostate, ovarian, and breast cancer. While metformin is a known adenosine monophosphate-activated protein kinase (AMPK) agonist and an inhibitor of the electron transport chain complex I, its mechanism of action in cancer cells as well as its effect on cancer metabolism is not clearly established. In this review, we will give an update on the role of metformin as an antitumoral agent and detail relevant evidence on the potential use and mechanisms of action of metformin in cancer. Analyzing antitumoral, signaling, and metabolic impacts of metformin on cancer cells may provide promising new therapeutic strategies in oncology. | |
| dc.identifier.doi | 10.17863/CAM.84774 | |
| dc.identifier.eissn | 1424-8247 | |
| dc.identifier.issn | 1424-8247 | |
| dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/337360 | |
| dc.language | en | |
| dc.publisher | MDPI AG | |
| dc.subject | metformin | |
| dc.subject | diabetes | |
| dc.subject | cancer metabolism | |
| dc.subject | AMPK | |
| dc.subject | PI3K | |
| dc.subject | therapeutics | |
| dc.subject | drug repurposing | |
| dc.title | Metformin and Cancer, an Ambiguanidous Relationship. | |
| dc.type | Article | |
| dcterms.dateAccepted | 2022-05-12 | |
| prism.issueIdentifier | 5 | |
| prism.publicationName | Pharmaceuticals (Basel) | |
| prism.volume | 15 | |
| rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0/ | |
| rioxxterms.version | VoR | |
| rioxxterms.versionofrecord | 10.3390/ph15050626 |
Files
Original bundle
1 - 3 of 3
No Thumbnail Available
- Name:
- additional-files.zip
- Size:
- 218.8 KB
- Format:
- ZIP file
- Description:
- Supporting information
- Licence
- https://creativecommons.org/licenses/by/4.0/
No Thumbnail Available
- Name:
- pharmaceuticals-15-00626.xml
- Size:
- 8.54 KB
- Format:
- Extensible Markup Language
- Description:
- Bibliographic metadata
- Licence
- https://creativecommons.org/licenses/by/4.0/
Loading...
- Name:
- pharmaceuticals-15-00626-v2.pdf
- Size:
- 1.28 MB
- Format:
- Adobe Portable Document Format
- Description:
- Published version
- Licence
- https://creativecommons.org/licenses/by/4.0/